Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 6 (2009), Issue 2 (February)

1. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.
   Neurology, 72(5): 402-9. [Abstract] [Full-text]
2. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.
   Radiology, 250(2): 506-14. [Abstract] [Full-text]
3. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
   Neurology, 72(5): 396-401. [Abstract] [Full-text]
4. An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
   Brain Res, 1255: 148-52. [Abstract] [Full-text]
5. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.
   Brain Res, 1256: 123-8. [Abstract] [Full-text]
6. Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis.
   J Pathol, 217(4): 543-51. [Abstract] [Full-text]
7. Demyelinating events in early multiple sclerosis have inherent severity and recovery.
   Neurology, 72(7): 602-8. [Abstract] [Full-text]
8. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.
   Neurology, 72(7): 595-601. [Abstract] [Full-text]
9. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients.
   J Neurol Neurosurg Psychiatry, 80(3): 292-6. [Abstract] [Full-text]
10. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis.
    Lancet Neurol, 8(3): 280-91. [Abstract] [Full-text]
11. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Lancet Neurol, 8(3): 254-60. [Abstract] [Full-text]
12. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Lancet Neurol, 8(3): 244-53. [Abstract] [Full-text]
13. Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis.
    Neuroimage, 45(2): 500-11. [Abstract] [Full-text]
14. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders.
    Neurology, 72(8): 712-7. [Abstract] [Full-text]
15. MRI as an outcome in multiple sclerosis clinical trials.
    Neurology, 72(8): 705-11. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.